StockData
NWBOOTCPharmaceutical PreparationsFiscal year ends December 31

NORTHWEST BIOTHERAPEUTICS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.16−0.00 (-0.88%)

Close on Oct 19, 2026

Market cap
$254.79M
P/E (TTM)
–
Dividend yield
–

Earnings

Quarterly results announced on Form 8-K, Item 2.02

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2013
Ended Jun 30, 2013
Aug 9, 2013Before market open–––
Q1 FY2013
Ended Mar 31, 2013
Apr 8, 2013During market hours–––

Press releases

Announcements Northwest Biotherapeutics filed with the SEC

  • FORM 8-K

    Event dated Jul 29, 2026, from SEC EDGAR

  • FORM 8-K

    Event dated Jul 17, 2026, from SEC EDGAR

  • FORM 8-K

    Event dated Oct 24, 2025, from SEC EDGAR

  • FORM 8-K

    Event dated Jan 15, 2026, from SEC EDGAR

  • FORM 8-K

    Event dated Dec 29, 2025, from SEC EDGAR

  • FORM 8-K

    Event dated Nov 14, 2025, from SEC EDGAR

  • FORM 8-K

    Event dated Oct 27, 2025, from SEC EDGAR

  • FORM 8-K

    Event dated Oct 24, 2025, from SEC EDGAR

  • FORM 8-K

    Event dated Oct 23, 2025, from SEC EDGAR

  • FORM 8-K

    Event dated Oct 9, 2025, from SEC EDGAR

  • FORM 8-K

    Event dated Dec 19, 2024, from SEC EDGAR

  • FORM 8-K

    Event dated Oct 31, 2024, from SEC EDGAR

  • FORM 8-K

    Event dated Aug 2, 2024, from SEC EDGAR

  • FORM 8-K

    Event dated Jun 29, 2024, from SEC EDGAR

  • FORM 8-K

    Event dated May 31, 2024, from SEC EDGAR